The first half’s laggards—financial ETFs—could turn out to be a second-half surprise.
Biotech is looking interesting again; here’s how to play it.
If you’re looking to profit from the growing array of sophisticated cancer treatments, look no further than biotech ETFs. But the devil’s in the details, as the five choices available to investors make clear.
Three funds are outperforming the broader stock market. And these ETFs appear to have strong fundamentals as longer-term portfolio plays.